MARKET

HRMY

HRMY

Harmony Biosciences Holdings, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.17
-0.86
-2.32%
Closed 16:08 01/26 EST
OPEN
36.80
PREV CLOSE
37.03
HIGH
37.14
LOW
35.52
VOLUME
151.39K
TURNOVER
--
52 WEEK HIGH
52.74
52 WEEK LOW
28.97
MARKET CAP
2.28B
P/E (TTM)
-15.7948
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Harmony Biosciences To Be Added To Russell 2000® And Russell 3000® Indexes
and , /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical need...
PR Newswire - PRF · 12/17/2020 13:05
Harmony Biosciences To Be Added To Russell 2000® And Russell 3000® Indexes
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the ...
PR Newswire · 12/17/2020 13:05
Harmony Biosciences initiates mid-stage study of Pitolisant in Prader-Willi Syndrome
Harmony Biosciences (HRMY) has enrolled the first patient in a Phase 2 trial evaluating the safety and efficacy of pitolisant for the treatment of excessive daytime sleepiness ((EDS)) and other key
Seekingalpha · 12/15/2020 14:12
Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and
Benzinga · 12/15/2020 13:08
Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome
, Pa. and , /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medica...
PR Newswire - PRF · 12/15/2020 13:05
Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the ...
PR Newswire · 12/15/2020 13:05
Is HRMY A Good Stock To Buy Now?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money invest...
Insider Monkey · 12/10/2020 16:44
Akers Biosciences, Cidara Therapeutics leads healthcare gainers; Applied Therapeutics, Soliton among major losers
Gainers: Akers Biosciences (AKER) +45%, Cidara Therapeutics (CDTX) +29%, Five Prime Therapeutics (FPRX) +24%, Zhongchao (ZCMD) +22%, Vaxart (VXRT) +22%.Losers: Applied Therapeutics (APLT) -12%, Soliton (SOLY) -13%, Harmony Biosciences Holdings (HRMY) -10%, Can-Fite BioPharma (CANF) -10%, Oncternal Therapeutics (ONCT) -9%.
Seekingalpha · 11/12/2020 16:04
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HRMY. Analyze the recent business situations of Harmony Biosciences Holdings, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HRMY stock price target is 52.00 with a high estimate of 61.00 and a low estimate of 41.00.
EPS
Institutional Holdings
Institutions: 43
Institutional Holdings: 28.54M
% Owned: 45.31%
Shares Outstanding: 62.98M
TypeInstitutionsShares
Increased
0
0
New
43
28.54M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
About HRMY
Harmony Biosciences Holdings, Inc. is a holding company. The Company through its subsidiary, Harmony Biosciences, LLC., operates as a pharmaceutical company, which is focused on therapies for patients suffering from central nervous system disorders living with medical needs. It provides treatment options for people living with rare and orphan diseases, with an emphasis on central nervous system disorders, patients living with narcolepsy. It enables to know narcolepsy and provides information and resources to individuals who live with, and healthcare professionals who treat patients with, this disorder. Narcolepsy is a chronic, debilitating neurologic disorder of sleep-wake state instability. The Company’s product, WAKIX (pitolisant), is a molecule with an action, designed to histamine signaling in the brain by binding to H3 receptors.

Webull offers kinds of Harmony Biosciences Holdings Inc stock information, including NASDAQ:HRMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HRMY stock methods without spending real money on the virtual paper trading platform.